Literature DB >> 10836366

Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients.

V Hammarström1, K Pauksen, H Svensson, B Lönnqvist, B Simonsson, O Ringdén, P Ljungman.   

Abstract

BACKGROUND: The aim of this study was to investigate the correlation of total levels of immunoglobulins to levels of specific antibodies after allogeneic and autologous bone marrow transplantation. Autologous transplant patients had normal levels of IgA and IgG antibodies already at 6 months after transplantation. In allogeneic transplanted patients without chronic graft versus host disease the immunological recovery was slower. The IgA and IgG levels were at the limit for deficiency at 6 months after transplantation. In allogeneic transplant patients with chronic chronic graft versus host disease the immunological recovery was delayed further. The total IgG levels were low at 12 months after transplantation and the IgG subclass pattern did not normalize until 24 months after transplantation. IgA levels remained low at 24 months after transplantation in all allogeneic transplanted patients with chronic chronic graft versus host disease. Protective levels of specific antibodies against tetanus and pneumococci decreased during the first year after transplantation regardless of the total immunoglobulin levels, regardless of the donors immunity. Pneumococcal antibodies decreased only in allogeneic transplanted patients, although autologous transplant patients retained pretransplant immunity against pneumococci. There was no difference in levels of specific antibodies between patients with and without chronic chronic graft versus host disease at 12 months after transplantation. There was no correlation between total immunoglobulin levels to levels of specific antibodies against tetanus and pneumococci after transplantation in our study. Taken together, normalized immunoglobulin levels do not predict normalization of levels of specific antibodies against tetanus and pneumococci after transplantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836366     DOI: 10.1097/00007890-200004270-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).

Authors:  Jan Storek; Zhao Zhao; Eugene Lin; Thomas Berger; Peter A McSweeney; Richard A Nash; Yoshiki Akatsuka; Monja D Metcalf; Hailing Lu; Tomas Kalina; Markus Reindl; Rainer Storb; John A Hansen; Keith M Sullivan; George H Kraft; Daniel E Furst; David G Maloney
Journal:  Clin Immunol       Date:  2004-12       Impact factor: 3.969

2.  Long-term persistence of oligoclonal serum IgM repertoires in patients treated with allogeneic bone marrow transplantation (BMT).

Authors:  I N Björk; C Brissac; M Remberger; J Mattsson; S Klaesson; O Ringdén; J Stewart; I Lundkvist
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

3.  Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient.

Authors:  M Elias; N Bisharat; L H Goldstein; R Raz; W Saliba
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

Review 4.  Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.

Authors:  Sung-Yeon Cho; Hyeon-Jeong Lee; Dong-Gun Lee
Journal:  Korean J Intern Med       Date:  2018-02-27       Impact factor: 2.884

5.  Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Christine Eisfeld; Eva Eßeling; Ramona Wullenkord; Cyrus Khandanpour; Julia Reusch; Jan-Henrik Mikesch; Christian Reicherts; Andrea Kerkhoff; Christoph Schliemann; Torsten Kessler; Rolf M Mesters; Wolfgang E Berdel; Georg Lenz; Matthias Stelljes
Journal:  Ann Hematol       Date:  2020-05-22       Impact factor: 3.673

Review 6.  B Cell Reconstitution and Influencing Factors After Hematopoietic Stem Cell Transplantation in Children.

Authors:  Nicolaas G van der Maas; Dagmar Berghuis; Mirjam van der Burg; Arjan C Lankester
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

7.  High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.

Authors:  A K Blystad; H Holte; S Kvaløy; E Smeland; J Delabie; G Kvalheim
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.